Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III InnovateTM Trial — Judith Trotman (2021) | RDL Network
Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III InnovateTM Trial
Article 2021 en
Authors
JT
Judith Trotman
CB
Christian Buske
AT
Alessandra Tedeschi
Abstract
1 min read
In the final analysis from iNNOVATE, single-agent ibrutinib continued to show sustained efficacy in patients with heavily pretreated, rituximab-refractory Waldenström macroglobulinemia.
Judith Trotman, Christian Buske, Alessandra Tedeschi, Jeffrey Matous, D. Blair Macdonald, Constantine S. Tam, Olivier Tournilhac, Shuo Ma, Steven P. Treon, Albert Oriol, Jerry Ping, Eva M. Briso, Israel Arango‐Hisijara, Meletios A Dimopoulos
Judith Trotman, Christian Buske, Alessandra Tedeschi, Jeffrey Matous, D. Blair Macdonald, Constantine S. Tam, Olivier Tournilhac, Shuo Ma, Steven P. Treon, Albert Oriol, Jerry Ping, Eva M. Briso, Israel Arango‐Hisijara, Meletios A Dimopoulos
Meletios A Dimopoulos, Alessandra Tedeschi, Judith Trotman, Ramón García‐Sánz, D. Blair Macdonald, Véronique Leblond, Beatrice Mahé, Charles Herbaux, Constantine S. Tam, Lorella Orsucci, M. Lia Palomba, Jeffrey Matous, Chaim Shustik, Efstathios Kastritis, Steven P. Treon, Jianling Li, Zeena Salman, Thorsten Graef, Christian Buske
Discussion(0)
No comments yet. Be the first to comment.